^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

olaptesed pegol (NOX-A12)

i
Other names: NOX-A12, anti-CXCL12/SDF-1 Spiegelmer
Company:
TME Pharma
Drug class:
CXCL12 inhibitor
2ms
GLORIA: Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients (clinicaltrials.gov)
P1/2, N=117, Active, not recruiting, TME Pharma AG | N=27 --> 117 | Trial completion date: Dec 2024 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2028
Enrollment change • Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • temozolomide • olaptesed pegol (NOX-A12)
6ms
OPTIMUS: Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer (clinicaltrials.gov)
P2, N=60, Not yet recruiting, TME Pharma AG | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Oct 2026 --> Oct 2027
Trial completion date • Trial primary completion date • Metastases
|
Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • olaptesed pegol (NOX-A12)
6ms
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial. (PubMed, Nat Commun)
In a post-hoc exploratory analysis of tumor tissue, higher frequency of CXCL12+ endothelial and glioma cells was significantly associated with longer PFS under NOX-A12. Our data imply safety of NOX-A12 and its efficacy signal warrants further investigation.
P1/2 data • Clinical Trial,Phase I • Clinical Trial,Phase II • Journal
|
MGMT (6-O-methylguanine-DNA methyltransferase) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
olaptesed pegol (NOX-A12)
1year
Interim data on dual inhibition of post-radiogenic angio-vasculogenesis by olaptesed pegol (NOX-A12) and bevacizumab in glioblastoma from the first expansion arm of the phase 1/2 GLORIA trial. (SNO 2023)
Interim data of the ongoing trial confirm the previously established safety profile of NOX-A12 for combinatory treatment with bevacizumab while demonstrating improved efficacy with deeper and longer-lasting responses and a higher ORR compared to treatment with RT and NOX-A12 only.
P1/2 data
|
MGMT (6-O-methylguanine-DNA methyltransferase) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
Avastin (bevacizumab) • olaptesed pegol (NOX-A12)
1year
Modulation of immune landscape in glioblastoma by CXCL12 inhibition (SITC 2023)
8 In this study we aimed to address the role of CXCL12 and its inhibition by NOX-A12 (with and without immune checkpoint inhibitors, ICI) in modulating the immune landscape in mice bearing GBM...Conclusions Inhibition of CXCL12 resulted in a time-dependent array of changes in peripheral blood and tumor-bearing brains but no clear survival benefit. Whether immune-related brain edema, or insufficient activation of immune cells in TME contributed to this result will be clarified by comparing response between intracranial and flank tumor, to better understand the mechanism of immune cell trafficking and polarization mediated by CXCL12 in GBM.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD4 (CD4 Molecule) • MRC1 (Mannose Receptor C-Type 1) • SIGLEC1 (Sialic Acid Binding Ig Like Lectin 1)
|
CXCR4 expression
|
olaptesed pegol (NOX-A12)
over1year
Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial (ESMO 2023)
Conclusions m IF of matched pre-/post-therapy tissue samples from the ongoing GLORIA trial supports the proposed modes of action of RT and NOX-A12 counteracting vasculogenesis and modulating the iTME reflected through its spatial rearrangement. This opens up the question of a targetable, compartment-specific role of CXCL12 to be further assessed.
P1/2 data
|
MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
MGMT promoter methylation
|
olaptesed pegol (NOX-A12)
over1year
GLORIA: Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients (clinicaltrials.gov)
P1/2, N=27, Active, not recruiting, TME Pharma AG | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • olaptesed pegol (NOX-A12)
over1year
Potential predictive biomarker for response to radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial. (ASCO 2023)
We show superior clinical efficacy of RT and NOX-A12 in patients with high frequency of CXCL12 expressing endothelial and glioma cells, suggesting the use of the EG12 score as a novel predictive biomarker for CXCL12-directed therapies in GBM. Clinical trial information: NCT04121455.
P1/2 data
|
CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD68 (CD68 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • GFAP (Glial Fibrillary Acidic Protein)
|
CXCL12 expression
|
olaptesed pegol (NOX-A12)
over2years
Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMT-unmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial. (ASCO 2022)
Interim data from the ongoing GLORIA trial demonstrates safety of RT plus OLA and suggests promising clinical efficacy of a new class of drugs targeting CXCL12 in GBM.
Clinical • P1/2 data
|
MGMT (6-O-methylguanine-DNA methyltransferase) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • ACKR3 (Atypical Chemokine Receptor 3)
|
olaptesed pegol (NOX-A12)
over2years
The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies. (PubMed, Eur J Pharmacol)
Plerixafor, BKT140, LY2510924, PF-06747143, ulocuplumab, and NOX-A12 are among the most well-known CXCR4 and CXCL12 modulators that their therapeutic efficacies have been evaluated in different pre-clinical and clinical studies of hematologic malignancies. To have an overview of the importance of CXCL12/CXCR4 and CXCL12/CXCR7 axes in the pathogenesis of leukemia and to gather information about the latest advances as well as challenges in targeting these axes in clinical settings, the present review has begun with a discussion about how aberrant expression of CXCL12/CXCR4 and CXCL12/CXCR7 pathways might regulate leukemogenesis and ended by outlining the key news of preclinical and clinical investigations in leukemia treatment.
Review • Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • ACKR3 (Atypical Chemokine Receptor 3)
|
CXCL12 expression
|
olaptesed pegol (NOX-A12) • LY2510924 • ulocuplumab (BMS-936564) • Aphexda (motixafortide) • plerixafor
3years
CXCL12 inhibition in MGMT unmethylated glioblastoma – results of an early proof-of-concept assessment in the multicentric phase I/II GLORIA trial (NCT04121455) (SNO 2021)
Patients received continuous (24/7) i.v. infusions of 200mg/week (n=3), 400mg/week (n=3) or 600mg/week (n=3) of the CXCL12 inhibitor olaptesed pegol (OLA) for 26 weeks during and after normo- or hypofractionated RT (60Gy/40.05Gy)...CONCLUSIONS Advanced MRI and multiplexed immunofluorescence suggest efficacy of combined radiotherapy and CXCL12 inhibition in unmethylated GBM. Funded by NOXXON Pharma AG; ClinicalTrials.gov number, NCT04121455.
Clinical • P1/2 data
|
MGMT (6-O-methylguanine-DNA methyltransferase) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
olaptesed pegol (NOX-A12)
3years
GLORIA: Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients (clinicaltrials.gov)
P1/2, N=21, Recruiting, NOXXON Pharma AG | Active, not recruiting --> Recruiting | Trial completion date: Sep 2022 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Dec 2024
Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • olaptesed pegol (NOX-A12)
3years
Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects. (PubMed, J Immunother Cancer)
We demonstrate that the combination of CXCL12 inhibition and checkpoint inhibition is safe and grants further exploration of synergistic combinatorial strategies.
Clinical • Journal
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • IL16 (Interleukin 16)
|
Keytruda (pembrolizumab) • olaptesed pegol (NOX-A12)
over3years
CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5. (PubMed, Cell Death Dis)
However, blockade of CXCL12-CXCR4 signaling axis by inhibitors like Nox-A12, FDA approved CXCR4 inhibitor drug AMD3100 have shown limited clinical success in cancer treatment...In our pursuit to understand the impact of chemokine signaling in carcinogenesis, we reveal that instead of CXCR4-CXCL12 signaling, presence of CXCR4 intracellular protein augments paclitaxel resistance and pro-tumorigenic functions...Finally, performing TCGA data mining and using human breast cancer patient samples, we demonstrate that expression of CXCR4 and DR5 are inversely regulated. Together, our data suggest that targeting CXCR4 intracellular protein may be critical to dampen the pro-tumorigenic functions of CXCR4.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
paclitaxel • olaptesed pegol (NOX-A12) • plerixafor
over4years
Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions. (PubMed, Pharmacol Res)
It is therefore of great interest to investigate CXCR4/CXCR7/CXCL12 modulators in clinical development, with several CXCR4 and CXCL12 modulators such as plerixafor, ulocuplumab, balixafortide, and olaptesed pegol having already reached this stage...Contrary to CXCR4 and CXCL12 modulators, CXCR7 modulators have, thus far, not been extensively studied. Therefore, more (pre)clinical investigations are needed.
Review • Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
doxorubicin hydrochloride • Xtandi (enzalutamide capsule) • balixafortide (POL 6326) • olaptesed pegol (NOX-A12) • LY2510924 • ulocuplumab (BMS-936564) • Aphexda (motixafortide) • plerixafor
over4years
Clinical • P1/2 data
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
Keytruda (pembrolizumab) • olaptesed pegol (NOX-A12)
over4years
[VIRTUAL] Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer (AACR-I 2020)
A trend towards agglomeration of T cells within tumors was observed in about half of the patients where NOX-A12 had induced a Th1-type cytokine response. This agglomeration was accompanied by reduced distances between T cells and cancer cells, suggesting increased infiltration of effector immune cells into tumor tissue. Treatment with NOX-A12 plus pembrolizumab in the combination therapy part of the study resulted in stable disease in 25% of patients, and prolonged time on treatment vs.
Clinical • P1/2 data
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • IFNG (Interferon, gamma) • IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • olaptesed pegol (NOX-A12)